Pages that link to "Q51821205"
Jump to navigation
Jump to search
The following pages link to Control of rHuEPO biological activity: the role of carbohydrate (Q51821205):
Displaying 50 items.
- Designing cell-targeted therapeutic proteins reveals the interplay between domain connectivity and cell binding (Q28252009) (← links)
- Development of an in vitro Bioassay for Recombinant Human Erythropoietin (rHuEPO) Based on Proliferative Stimulation of an Erythroid Cell Line and Analysis of Sialic Acid Dependent Microheterogeneity: UT-7 Cell Bioassay. (Q30399757) (← links)
- Evaluation of epoetin alpha (rHuEPO) and darbepoetin alpha (DARB) on human burst-colony formation (BFU-E) in culture (Q33239436) (← links)
- Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy (Q33586660) (← links)
- Natural Form of Noncytolytic Flexible Human Fc as a Long-Acting Carrier of Agonistic Ligand, Erythropoietin (Q34034670) (← links)
- The effect of erythropoietin on normal and neoplastic cells (Q34291437) (← links)
- A biomathematical model of human erythropoiesis under erythropoietin and chemotherapy administration (Q34766672) (← links)
- Pharmacokinetics and pharmacodynamics of recombinant human EPO-Fc fusion protein in vivo (Q34974011) (← links)
- Erythropoietin (EPO) in acute kidney injury (Q35176135) (← links)
- The influence of artificially introduced N-glycosylation sites on the in vitro activity of Xenopus laevis erythropoietin (Q35610754) (← links)
- An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin. (Q35762997) (← links)
- In silico design and analysis of a new hyperglycosylated analog of erythropoietin to improve drug efficacy (Q35997019) (← links)
- Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration (Q36025060) (← links)
- Related effects of cell adaptation to serum-free conditions on murine EPO production and glycosylation by CHO cells (Q36254504) (← links)
- Production of homogeneous glycoprotein with multisite modifications by an engineered N-glycosyltransferase mutant. (Q36337312) (← links)
- Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575. (Q36354544) (← links)
- Cellular level models as tools for cytokine design (Q36393660) (← links)
- Epoetin beta in oncology: examining the current evidence (Q36429666) (← links)
- Modifications of therapeutic proteins: challenges and prospects (Q36495973) (← links)
- Biochemistry, physiology, and complications of blood doping: facts and speculation (Q36504354) (← links)
- Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study (Q36655932) (← links)
- Through the looking glass: the protein science of biosimilars (Q36949853) (← links)
- Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents (Q37308372) (← links)
- Cardiovascular Effects of Erythropoietin (Q37533151) (← links)
- Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact (Q37686245) (← links)
- Erythropoiesis stimulating agents: approaches to modulate activity (Q38121067) (← links)
- Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents (Q38126361) (← links)
- Identification of Methionine Oxidation in Human Recombinant Erythropoietin by Mass Spectrometry: Comparative Isoform Distribution and Biological Activity Analysis. (Q38616210) (← links)
- Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications (Q39149359) (← links)
- Plant-produced human recombinant erythropoietic growth factors support erythroid differentiation in vitro (Q39177665) (← links)
- Glycoengineering of CHO Cells to Improve Product Quality (Q39298073) (← links)
- Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease (Q39980622) (← links)
- Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). (Q40351752) (← links)
- Engineering of sialylated mucin-type O-glycosylation in plants (Q41770495) (← links)
- Increased Synthesis of Liver Erythropoietin with CKD. (Q41849952) (← links)
- Neuroprotection of photoreceptors by direct delivery of erythropoietin to the retina of the retinal degeneration slow mouse (Q41865596) (← links)
- Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia (Q41892226) (← links)
- Structural Identification of a Non-Glycosylated Variant at Ser126 for O-Glycosylation Site from EPO BRP, Human Recombinant Erythropoietin by LC/MS Analysis (Q42090477) (← links)
- European Union regulatory draft guidance on biogenerics containing recombinant human erythropoietin (Q42721318) (← links)
- GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins. (Q42825895) (← links)
- Measurement of Sialic Acid Content Is Insufficient to Assess Bioactivity of Recombinant Human Erythropoietin (Q42914629) (← links)
- Engineering of human-type O-glycosylation in Nicotiana benthamiana plants (Q43067528) (← links)
- Production of recombinant human erythropoietin/Fc fusion protein by genetically manipulated chickens (Q43298959) (← links)
- A kinetic-metabolic model based on cell energetic state: study of CHO cell behavior under Na-butyrate stimulation (Q44828146) (← links)
- Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients (Q48287588) (← links)
- Red blood cell erythropoietin, not plasma erythropoietin, concentrations correlate with changes in hematological indices in horses receiving a single dose of recombinant human erythropoietin by subcutaneous injection (Q50702959) (← links)
- High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study (Q50735246) (← links)
- Quantifying Western blots: pitfalls of densitometry (Q51822227) (← links)
- An oligosaccharyltransferase from Leishmania major increases the N-glycan occupancy on recombinant glycoproteins produced in Nicotiana benthamiana. (Q52373100) (← links)
- Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase. (Q54173895) (← links)